Cargando…

Targeting autophagy reverses de novo resistance in homologous recombination repair proficient breast cancers to PARP inhibition

BACKGROUND: Poly(ADP-ribose) polymerase inhibitors (PARPi) target tumours defective in homologous recombination (HR). Most BRCA-wild-type (WT) HR-proficient breast cancers are intrinsically resistant to PARP inhibitors, e.g., talazoparib. We evaluated the role of autophagy in this de novo resistance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pai Bellare, Ganesh, Saha, Bhaskar, Patro, Birija Sankar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007595/ https://www.ncbi.nlm.nih.gov/pubmed/33473172 http://dx.doi.org/10.1038/s41416-020-01238-0

Ejemplares similares

trans-4,4’-Dihydroxystilbene (DHS) inhibits human neuroblastoma tumor growth and induces mitochondrial and lysosomal damages in neuroblastoma cell lines
por: Saha, Bhaskar, et al.
Publicado: (2017)

SN-38 Sensitizes BRCA-Proficient Ovarian Cancers to PARP Inhibitors through Inhibiting Homologous Recombination Repair
por: Lin, Shengbin, et al.
Publicado: (2022)

Arsenic compound sensitizes homologous recombination proficient ovarian cancer to PARP inhibitors
por: Xu, Junfen, et al.
Publicado: (2021)

Targeting SMYD3 to Sensitize Homologous Recombination-Proficient Tumors to PARP-Mediated Synthetic Lethality
por: Sanese, Paola, et al.
Publicado: (2020)

Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer Cells
por: Gomez, Miriam K., et al.
Publicado: (2020)

PARP Inhibition in Prostate Cancer With Homologous Recombination Repair Alterations
por: von Werdt, Alexander, et al.
Publicado: (2021)

Synergistic lethality between PARP-trapping and alantolactone-induced oxidative DNA damage in homologous recombination-proficient cancer cells
por: Wang, Hongge, et al.
Publicado: (2020)

Homologous Recombination Repair in Biliary Tract Cancers: A Prime Target for PARP Inhibition?
por: Yin, Chao, et al.
Publicado: (2022)

Homologous recombination proficiency in ovarian and breast cancer patients
por: Creeden, Justin Fortune, et al.
Publicado: (2021)

PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components
por: O’Sullivan Coyne, Geraldine, et al.
Publicado: (2022)

Breaking the Iron Homeostasis: A “Trojan Horse” Self-Assembled Nanodrug Sensitizes Homologous Recombination Proficient Ovarian Cancer Cells to PARP Inhibition
por: Li, Yangyang, et al.
Publicado: (2022)

ATR inhibition reverses the resistance of homologous recombination deficient MGMT(low)/MMR(proficient) cancer cells to temozolomide
por: El Touny, Lara H., et al.
Publicado: (2021)

BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair
por: Zhang, Shaolu, et al.
Publicado: (2021)

Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
por: Chopra, Neha, et al.
Publicado: (2020)

Non‐enzymatic function of WRN RECQL helicase regulates removal of topoisomerase‐I‐DNA covalent complexes and triggers NF‐κB signaling in cancer
por: Gupta, Pooja, et al.
Publicado: (2022)

Repression of LSD1 potentiates homologous recombination-proficient ovarian cancer to PARP inhibitors through down-regulation of BRCA1/2 and RAD51
por: Tao, Lei, et al.
Publicado: (2023)

The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors
por: Peng, Yihan, et al.
Publicado: (2019)

Loss of CtIP disturbs homologous recombination repair and sensitizes breast cancer cells to PARP inhibitors
por: Wang, Junhui, et al.
Publicado: (2015)

PARP1 suppresses homologous recombination events in mice in vivo
por: Claybon, Alison, et al.
Publicado: (2010)

Editorial: TGF-β signalling pathways and their enigmatic role as a friend and foe in human health and diseases
por: Betapudi, Venkaiah, et al.
Publicado: (2023)

Targeting DNA Homologous Repair Proficiency With Concomitant Topoisomerase II and c-Abl Inhibition
por: Siddiqui, Arafat, et al.
Publicado: (2021)

Homologous recombination repair intermediates promote efficient de novo telomere addition at DNA double-strand breaks
por: Davé, Anoushka, et al.
Publicado: (2020)

CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors
por: Lu, Xue, et al.
Publicado: (2022)

ATR Inhibitor Synergizes PARP Inhibitor Cytotoxicity in Homologous Recombination Repair Deficiency TK6 Cell Lines
por: Wikiniyadhanee, Rakkreat, et al.
Publicado: (2023)

Methylated-UHRF1 and PARP1 interaction is critical for homologous recombination
por: Hahm, Ja Young, et al.
Publicado: (2020)

WIP1 Promotes Homologous Recombination and Modulates Sensitivity to PARP Inhibitors
por: Burdova, Kamila, et al.
Publicado: (2019)

LRRK2 inhibition potentiates PARP inhibitor cytotoxicity through inhibiting homologous recombination‐mediated DNA double strand break repair
por: Chen, Lifeng, et al.
Publicado: (2021)

Loss of CENP-I Impairs Homologous Recombination and Sensitizes Cells to PARP1 Inhibition
por: Dang, Tuyen T., et al.
Publicado: (2021)

Loss of NFBD1/MDC1 disrupts homologous recombination repair and sensitizes nasopharyngeal carcinoma cells to PARP inhibitors
por: Wang, Zhihai, et al.
Publicado: (2019)

Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors
por: Criscuolo, Daniela, et al.
Publicado: (2019)

hMOB2 deficiency impairs homologous recombination-mediated DNA repair and sensitises cancer cells to PARP inhibitors
por: Gundogdu, Ramazan, et al.
Publicado: (2021)

Berberine induces oxidative DNA damage and impairs homologous recombination repair in ovarian cancer cells to confer increased sensitivity to PARP inhibition
por: Hou, Dong, et al.
Publicado: (2017)

Excess Polθ functions in response to replicative stress in homologous recombination-proficient cancer cells
por: de Rugy, T. Goullet, et al.
Publicado: (2016)

PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers
por: Keung, Man Yee T., et al.
Publicado: (2019)

Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancers
por: Janysek, Dawn C., et al.
Publicado: (2021)

COMPROMISED CDK1 ACTIVITY SENSITIZES BRCA-PROFICIENT CANCERS TO PARP INHIBITION
por: Johnson, Neil, et al.
Publicado: (2011)

Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells
por: Choi, Young Eun, et al.
Publicado: (2014)

De novo phosphorylation of H2AX by WSTF regulates transcription-coupled homologous recombination repair
por: Ji, Jae-Hoon, et al.
Publicado: (2019)

Targeting MALAT1 Augments Sensitivity to PARP Inhibition by Impairing Homologous Recombination in Prostate Cancer
por: Yadav, Anjali, et al.
Publicado: (2023)

Effect of Autophagy Inhibitors on Radiosensitivity in DNA Repair-Proficient and -Deficient Glioma Cells
por: Saleh, Tareq, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ppe4r1qm58ukqjbjcoo2lbh1mb